LON:VER Vernalis (VER) Share Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range 6.17▼ 6.1752-Week Range N/AVolume11,076 shsAverage Volume1.22 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Vernalis alerts: Email Address Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Vernalis Stock (LON:VER)Vernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. It is also has licensing agreement to develop and commercialize various products focused on the U.S. prescription cough-cold market. In addition, the company is developing V158866, a fatty acid amide hydrolase inhibitor for the treatment of pain; CPI-444, an adenosine A2A receptor antagonist, which is in Phase I/Ib clinical trial to treat patients with various solid tumors; and AUY922, an intravenous Hsp90 inhibitor for treating cancer, as well as CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukemia and myelodysplastic syndrome under Phase II trial. Further, it is developing S55746, a selective Bcl-2 inhibitor that is in Phase I study for the treatment of cancer; V158411 molecule; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc.; Biogen Idec; Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc.; Novartis Pharma AG; Servier Research Group; GlaxoSmithKline plc; Genentech; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.Read More Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << VER Stock News HeadlinesSeptember 5 at 3:56 AM | msn.comBest Shrubs for Fall Leaf ColorAugust 23, 2024 | msn.comDo you know all 28 species of snakes in Iowa? Here's how you can identify them:September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 20, 2024 | msn.comHighway 132 partially shut down after head-on crash near VernalisAugust 16, 2024 | msn.comFrom the archives: Laci Peterson murder case has deep ties to SJAugust 12, 2024 | msn.comCompanion Plants That Will Safeguard Your Rosemary Plants From PestsAugust 10, 2024 | msn.comInjury crash reported on Highway 33 in San Joaquin CountyApril 29, 2024 | msn.comWhat to plant in zone 4: expert advice on the plants that will thriveSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.April 17, 2024 | msn.comReports of partial road closure from vehicle fire on Highway 33 in VernalisApril 3, 2024 | yahoo.comHow much water can Stanislaus farms and cities expect as growing season gets underway?March 27, 2024 | msn.com'Just staggering': UN says households waste 1b meals a dayMarch 17, 2024 | msn.comElvish Yadav case: What is snake venom and its lethal side as recreational drug?March 17, 2024 | msn.comDr. Kevin Korus: February showers bring March flowersFebruary 18, 2024 | msn.comBest winter flowers for scent – 12 uplifting plants to growJanuary 23, 2024 | msn.comHow does your car insurance rate compare to other cities in California?December 27, 2023 | msn.comBack to the yearly grind: San Francisco holds first holiday tree recycling event since COVIDDecember 26, 2023 | sfgate.comAnnual Chipping Of Christmas Trees Event Held For First Time After 3-Year HiatusSee More Headlines Receive VER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vernalis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/12/2017Today9/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:VER CUSIPN/A CIKN/A Webwww.vernalis.com Phone+44-118-9380000FaxN/AEmployees350Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Ian R. Garland (Age 52)CEO & Exec. Director Mr. David MacKney (Age 50)CFO & Exec. Director Ms. Susan WallcraftGroup Gen. Counsel & Company Sec.Mr. Joseph CannyVP of MarketingMs. Donna RadzikSr. VP of Pharmaceutical Quality OperationsKey CompetitorsAbzenaLON:ABZABTGLON:BTGAbcamLON:ABCGenusLON:GNSOxford Nanopore TechnologiesLON:ONTView All Competitors VER Stock Analysis - Frequently Asked Questions How were Vernalis' earnings last quarter? Vernalis plc (LON:VER) posted its quarterly earnings results on Tuesday, September, 12th. The company reported ($4.10) earnings per share for the quarter, topping analysts' consensus estimates of ($4.50) by $0.40. The company earned $20.79 million during the quarter. How do I buy shares of Vernalis? Shares of VER stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Vernalis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vernalis investors own include Lloyds Banking Group (LLOY), Filtronic (FTC), Entain PLC (GVC.L) (GVC), Oxford Biomedica (OXB), Assura (AGR) and Arsanis (ASNS). This page (LON:VER) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vernalis plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vernalis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.